Developer of multi-specific antibodies for cancer treatment. It offers tri-specific immuno-oncology antibody candidates which include KJ-101 for neuroendocrine solid tumors, KJ-102 for acute myeloid leukemia, and KJ-103 for TROP-2 Expressing solid tumors.
← All startups
KisoJi
Series BDeveloper of multi-specific antibodies for cancer treatment. It offers tri-specific immuno-oncology antibody candidates which include KJ-101 for neuroendocrine solid tumors, KJ-102 for acute myeloid leukemia, and KJ-103 for TROP-2 Expressing solid tumors.
About
Institutional investors
Invest QuebecLumira VenturesFonds de solidarite FTQadMare BioInnovationsRemiges VenturesAccel-Rx
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.